Qiagen Buys STAT-Dx To Launch Next-Gen Syndromic Testing System
Executive Summary
Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.
You may also be interested in...
Catalan Biotechs Boosted By International Backers
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.
M&A Analysis: January, Crisp Start To The Year
2018 kicked off with 17 medtech M&A deals in January, an increase from the 12 transactions recorded in the same period last year. The month also saw major medtech players reel in some significant acquisitions.